Mode
Text Size
Log in / Sign up

T1D MAPS polygenic score improves discrimination in non-EUR populations compared to T1D GRS2New genetic scores improve risk prediction for type 1 diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that T1D MAPS provides superior discrimination in non-EUR populations compared to T1D GRS2.

This meta-analysis evaluates the performance of various polygenic risk scores (GRS) for Type 1 Diabetes, including T1D GRS2, T1D GRS2', T1D GRSHLA, T1GRS, TA-PS, TA-PS (S), and T1D MAPS. The analysis utilized data from multiple biobanks to assess predictive accuracy across different populations.

Key findings indicate that T1D GRS2 and T1D MAPS showed the highest AUC in the All of Us cohort. Specifically, in the meta-analysis of non-EUR populations, T1D MAPS showed significantly improved discrimination compared to T1D GRS2, with a Delta AUC of 0.049 (p-value 1.7x10-7).

The authors note that T1D MAPS improves prediction in non-EUR populations, highlighting the importance of multi-ancestry approaches for equitable genetic risk prediction. However, the study evaluates genetic risk prediction models rather than clinical outcomes. Clinical application of these scores is currently limited to research contexts regarding genetic risk prediction.

How this fits prior evidence

This finding addresses a gap in equitable genetic risk prediction by identifying a polygenic score that performs better in non-EUR populations. While prior coverage has focused on clinical management, such as automated insulin delivery systems for older adults and finerenone for patients with Type 1 Diabetes and CKD, this study provides evidence on the underlying genetic risk prediction models used in research.

Predicting who will develop type 1 diabetes is a major challenge for doctors and families. Because genetics play a huge role, researchers use "polygenic scores" to estimate risk. These are essentially scores that combine many different genetic markers to see how likely a person is to develop the condition.

Researchers compared several of these scoring systems using data from over 500,000 people. They found that a specific model called T1D MAPS performed better than previous models. Specifically, T1D MAPS showed much better results when looking at people who were not of European descent. This is important because many older tools were not designed to work well for diverse populations.

While these scores are helpful for predicting risk, it is important to remember that they do not predict clinical outcomes like how a person will feel or how they will respond to treatment. The study highlights that using multi-ancestry data helps create more equitable tools for everyone.

What this means for you:
A new genetic tool called T1D MAPS provides more accurate risk predictions for diverse populations.

Common questions

How does this new genetic score help people with type 1 diabetes?

The new score, called T1D MAPS, improves how well doctors can predict the risk of type 1 diabetes. It is especially helpful because it works better for people who are not of European descent. This means the tool is more accurate for a wider range of people than previous models.

What is a polygenic score in this study?

A polygenic score is a way to measure risk by looking at many different genetic markers at once. Researchers used several of these scores to see which one was best at identifying who might develop type 1 diabetes. T1D MAPS was found to be more accurate than the older T1D GRS2 score.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Most polygenic scores (PS) for type 1 diabetes were developed using European (EUR) ancestry datasets, limiting performance in non-European (non-EUR) populations. We evaluated novel type 1 diabetes PS across diverse populations to assess whether newer models improve prediction in underrepresented populations. Seven type 1 diabetes PS (T1D GRS2, T1D GRS2', T1D GRSHLA, T1GRS, TA-PS, TA-PS (S), T1D MAPS) were evaluated in All of Us and Mass General Brigham Biobank. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC). T1D GRS2 and T1D MAPS showed the highest AUC in All of Us, while other scores demonstrated comparatively lower performance. These highest-performing scores were then evaluated in a meta-analysis across three additional biobanks (Genomic Health Initiative at Endeavor Health, Penn Medicine BioBank, Geisinger MyCode). Among 2,782 individuals with type 1 diabetes and 546,577 controls, T1D MAPS showed comparable performance to T1D GRS2 in EUR populations but significantly improved discrimination in non-EUR populations (meta-analysis {Delta}AUC=0.049, p=1.7x10-7). Overall, T1D MAPS improves prediction in non-EUR populations, highlighting the importance of multi-ancestry approaches for equitable genetic risk prediction. These findings could inform precision medicine in diverse populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.